Becton Dickinson (BDX) Q4 2026 Earnings Call Transcript

BD reported Q4 FY2026 revenue of $5.3 billion, up 5.6% currency-neutral, and adjusted diluted EPS of $4.15, up 27.3%; full-year free cash flow rose 42% to $2.9 billion. For FY2027, management forecasts low-single-digit revenue growth and adjusted EPS of $13.10–$13.30, citing an approximately 200-basis-point Alaris comparison headwind and inflation; adjusted operating margin is expected to be roughly flat. The company returned $3.6 billion to shareholders in FY2026, including $2.4 billion in repurchases and $1.2 billion in dividends, and said possible Section 232 tariff relief is not included in guidance. Management highlighted 95% Incada AI attachment on new Pyxis orders and expects sustainable mid-single-digit growth after the Alaris comparison rolls off.

Analysis

The setup is better than the headline growth guide implies, but the quality of the bridge matters. The Alaris comparison and a one-quarter APM systems cutover can depress reported growth without signaling weaker demand; however, any Q1 shipment deferral is timing, not incremental sales, and should be verified in Q2. The more durable earnings support is productivity and mix, while FY27’s flat margin outlook signals that inflation and commercial/R&D spending are absorbing near-term gains. That makes the promised margin flywheel a 6–18 month execution thesis, not yet a near-term earnings catalyst.

Do not capitalize Incada’s 95% attachment as software economics without evidence on paid conversion, recurring revenue, retention, and customer ROI. Likewise, FY26 free-cash-flow growth benefited from working-capital and remediation comparisons; the path toward 90% conversion needs cash-flow—not just EPS—confirmation. Buybacks support per-share results but compete with debt reduction and tuck-in M&A at 2.7x net leverage.

For the next 1–3 months, the Dec. 10 investor day and Q1/Q2 shipment pattern are the key tests. Section 232 relief is upside optionality, not base-case value: scope, timing, and milestone conditions remain unresolved. Contrarian risk is that investors treat strong Q4 execution as proof of immediate acceleration, while management’s conservative guide and flat margins imply a slower conversion. A sustained miss to underlying mid-single-digit growth or failure to expand margins after the Alaris comparison rolls off would falsify the bull case.

Key Decisions for Investors

• Prefer a staged long BDX on weakness over chasing the Q4 print; add only if Q1/Q2 confirms APM demand converts to shipments and underlying growth remains around mid-single digits. Reassess after the Dec. 10 investor day; no price target without valuation data.
• Treat Section 232 relief as an event-driven upside watch, not an earnings assumption. Re-rate only after tariff scope, effective date, and BD’s exemption eligibility are confirmed; a delay or restrictive scope removes this optionality.
• Track free cash flow conversion, net leverage, and buyback pace together. If conversion stalls while repurchases remain elevated, favor debt reduction over assuming buybacks can sustain EPS support.
• Monitor Incada paid adoption/recurring revenue and FY27 gross-margin delivery. High device attachment without monetization, or continued margin stagnation after the Alaris comparison normalizes, weakens the multiple-expansion thesis.